Tesamorelin

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This draft reviews trial evidence and product-specific U.S. labeling; it is not personal medical advice.

What the sources say

A smaller randomized trial in adults with HIV reported lower visceral fat and liver fat after treatment, but its authors described the findings as preliminary; it does not establish benefit for general weight loss or long-term liver outcomes. (Human clinical trials; Stanley et al., "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation," JAMA, 2014-07-23)
In a randomized trial of adults with HIV and abdominal-fat accumulation, visceral adipose tissue fell by 15.2% with tesamorelin and rose by 5.0% with placebo; lipid measures improved, while glycemic measures did not differ significantly. These results are specific to the studied population. (Human clinical trials; Falutz et al., "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV," New England Journal of Medicine, 2007-12-06)
The pivotal randomized study compared tesamorelin with placebo as a single agent; that study design does not demonstrate a benefit from adding another peptide or a "stack." No direct combination benefit is established by this source. (Human clinical trials; Falutz et al., "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV," New England Journal of Medicine, 2007-12-06)
The U.S. label indicates tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy and explicitly says it is not indicated for weight-loss management. (Manufacturer information; U.S. Food and Drug Administration, EGRIFTA WR (tesamorelin) for injection: Prescribing Information; checked 2026-10-28, 2026-10-28)
The FDA label lists disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy as contraindications. It warns about elevated IGF-1, possible fluid retention, glucose intolerance or diabetes, hypersensitivity, and increased mortality in acute critical illness. (Manufacturer information; U.S. Food and Drug Administration, EGRIFTA WR (tesamorelin) for injection: Prescribing Information; checked 2026-10-28, 2026-10-28)
Commonly reported adverse reactions in the label include joint pain, injection-site redness or itching, limb pain, peripheral edema, and muscle pain. The frequency and safety of unapproved preparations or long-term unsupervised use are not established by the branded-product label. (Manufacturer information; U.S. Food and Drug Administration, EGRIFTA WR (tesamorelin) for injection: Prescribing Information; checked 2026-10-28, 2026-10-28)
TGA guidance warns that unapproved peptide products may have uncertain identity, quality, sterility, or safety; those general risks should not be misrepresented as tesamorelin-specific trial findings. (Educator material (not peer reviewed); Therapeutic Goods Administration, "Understanding your responsibilities when importing, compounding and supplying unapproved peptide products", 2026-04-13)
No tesamorelin product record was located in the public ARTG search reviewed on 2026-10-28. This is a negative search result, not a legal certificate that covers every possible access pathway. (Educator material (not peer reviewed); Therapeutic Goods Administration, Australian Register of Therapeutic Goods (ARTG) search; checked 2026-10-28, 2026-10-28)
The October 2026 Poisons Standard is the current instrument reviewed. This draft does not assign a tesamorelin-specific Schedule because no substance-specific classification was verified in the materials reviewed; scheduling and ARTG registration are separate questions. (Educator material (not peer reviewed); Federal Register of Legislation, Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, 2026-09-30)
TGA states that therapeutic goods not included in the ARTG are unapproved unless a specific exemption or other lawful pathway applies, and that unapproved peptide products have not been assessed by TGA for safety, quality, or effectiveness. (Educator material (not peer reviewed); Therapeutic Goods Administration, "Understanding your responsibilities when importing, compounding and supplying unapproved peptide products", 2026-04-13)

Sources

Dosing, stacking and protocol details are not published here.